DOI: 10.1002/ame2.12076
The multiple-kinase inhibitor lenvatinib inhibits the proliferation of acute myeloid leukemia cells
Fan Feng
Xiaojuan Li
Ruisheng Li
Boan Li
摘要：Background: Current chemotherapy for acute myeloid leukemia (AML) mainly in-volves cytotoxic agents such as doxorubicin (DNR), mitoxantrone (Mito) or 2-ami-nopurine-6-thiol (6-TG). However, because these agents are relatively ineffective, discovering other more effective drugs for AML treatment would be valuable. Methods: The in vitro antitumor effect of lenvatinib on AML cells was examined using the colorimetric MTT assay for assessing cell metabolic activity. AML cells mixed with Poloxamer 407 were injected into nude mice to form subcutaneous tumors. Tumor-bearing mice received lenvatinib by oral administration. The antitumor effect of len-vatinib was established by measuring tumor volumes and weights. Results: Lenvatinib inhibited the growth of AML cells in a dose-dependent manner. We used AML cells to establish subcutaneous tumor tissues by mixing the cell sus-pension with Poloxamer 407. Poloxamer 407 alone did not influence the subcutane-ous growth of AML cells. Treatment of lenvatinib inhibited in vivo tumor growth of AML cells. Conclusion: The multiple-kinase inhibitor lenvatinib inhibits the in vitro proliferation of AML cells, and restricts the in vivo growth of AML tumors.
机标关键词：
论文发表日期：2019-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：7( 178-184 )
英文信息